Text Size:AAA
留言    收藏

PD-L1 / B7-H1 / CD274 抗體 (APC), 兔單抗

  • Coagulation Factor X / F10 Antibody, Mouse MAb, Immunohistochemistry
產品資料評論相關產品實驗方法
小鼠 CD274 抗體產品資訊
免疫原:Recombinant Mouse PD-L1 / B7-H1 / CD274 protein (Catalog#50010-M08H)
Clone ID:485
Ig類型:Rabbit IgG
濃度:5 μl/Test, 0.1 mg/ml
緩衝液:Aqueous solution containing 0.5% BSA and 0.09% sodium azide
抗體製備方法:This antibody was obtained from a rabbit immunized with purified, recombinant Mouse PD-L1 / B7-H1 / CD274 (rM PD-L1 / B7-H1 / CD274; Catalog#50010-M08H; NP_068693.1; Met1-Thr238) and conjugated with APC under optimum conditions, the unreacted APC was removed.
小鼠 CD274 Antibody FC Application Image
Coagulation Factor X / F10 Antibody, Mouse MAb, Immunohistochemistry
[點擊查看大圖]
Caption:
PD-L1 / B7-H1 / CD274 Antibody (APC), Rabbit MAb, Flow cytometric analysis
Other CD274 Antibody Products
PD-L1/B7-H1/CD274 研究背景

Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. PD-L1/B7-H1 is a member of the growing B7 family of immune molecules and this protein contains one V-like and one C-like Ig domain within the extracellular domain, and together with PD-L2, are two ligands for PD1 which belongs to the CD28/CTLA4 family expressed on activated lymphoid cells. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.

Immune Checkpoint
Immune Checkpoint Blockade: Blocking Antibodies   Immune Checkpoint Blockade: PD-L1 / B7-H1 / CD274 Blocking Antibodies
Immune Checkpoint Detection: Antibodies   Immune Checkpoint Detection: ELISA Antibodies   Immune Checkpoint Detection: IHC Antibodies   Immune Checkpoint Detection: ICC Antibodies   Immune Checkpoint Detection: FCM Antibodies   Immune Checkpoint Detection: WB Antibodies
Immune Checkpoint Proteins   PD-L1 / B7-H1 / CD274 Immune Checkpoint Proteins
Immune Checkpoint Targets   Co-inhibitory Immune Checkpoint Targets

Immunotherapy   Cancer Immunotherapy   Targeted Therapy

小鼠 PD-L1/B7-H1/CD274 參考資料
  • Iwai Y, et al. (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 99(19): 12293-7.
  • Ghebeh H, et al. (2006) The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia. 8(3): 190-8.
  • Salih HR, et al. (2006) The role of leukemia-derived B7-H1 (PD-L1) in tumor-T-cell interactions in humans. Exp Hematol. 34(7): 888-94.
  • Wilcox RA, et al. (2009) B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood. 114(10): 2149-58.
  • Ruggiero A, et al. (2009) Crystal structure of PD-L1, a ribosome inactivating protein from Phytolacca dioica L. leaves with the property to induce DNA cleavage. Biopolymers. 91(12): 1135-42.
  • Product nameProduct name
    Size / Price
    貨號: 50010-R485-A-25
    目錄價: 
    單價:      (You Save: )

    Datasheet & Documentation

    All information of our products is subject to change without notice. Please refer to COA enclosed in shipped package for the newest information.
    請注意:所有產品都是“僅用於科研,而不能用於診斷或治療用途”